SAU:4018

Almoosa Health Company · SAU · Healthcare · SAR · FY for 2025

Figures on this page computed 2026-11-08 12:42 UTC

Last close

n/aSAR

Market data

  • 19.8xP/E

    Price / Earnings per Share (diluted)

    Source
    computed
    Taken on
    2026-11-08
    Reported in
    SAR
    • computed
    • Computed from the filing for 2025
  • 7.5%ROIC

    NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash

    Source
    computed
    Taken on
    2026-11-08
    Reported in
    SAR
    • Computed from the filing for 2025
    • Computed from the filing for 2025
    • Computed from the filing for 2025
    • Computed from the filing for 2025
    • Computed from the filing for 2025
    • Computed from the filing for 2025
  • 16.7%Net margin

    Net Income / Revenue x 100

    Source
    computed
    Taken on
    2026-11-08
    Reported in
    SAR
    • Computed from the filing for 2025
    • Computed from the filing for 2025
  • -24.5%FCF margin

    Free Cash Flow / Revenue x 100

    Source
    computed
    Taken on
    2026-11-08
    Reported in
    SAR
    • Computed from the filing for 2025
    • Computed from the filing for 2025
  • 0.42Debt/equity

    Total Debt / Shareholders' Equity

    Source
    computed
    Taken on
    2026-11-08
    Reported in
    SAR
    • Computed from the filing for 2025
    • Computed from the filing for 2025
  • n/aDividend yield

    We do not hold this figure for this company, so there is nothing to place.

    Source
    computed
    Taken on
    2026-11-08
    Reported in
    SAR
    • computed

Five bars, one line

lens 7 of 9
1.48x
2.19x
1.37x
0.97x
n/a
SalesProfitFree cash flowDebtPrice
Each bar against this company's own average; the line is that average.
Computed2025
Computed2025
Computed2025
Computed2025
Market datan/a

Each against its own average

4 of 5 read

Except where said otherwise: Computed from the filing for 2025

  • Sales1.48x

    Its own average over 6 years, 957.4M.

  • Profit2.19x

    Its own average over 6 years, 107.9M.

  • Free cash flow1.37x

    Its own average over 6 years, -253.6M.

  • Debt0.97x

    Its own average over 6 years, 835.9M.

  • Pricen/a

    Its own average over 0 years. Market data

Profit is furthest from its own average, at 2.19 times.

Sales is 1.48 times its own 6-year average; Profit is 2.19 times its own 6-year average; Free cash flow is 1.37 times its own 6-year average; Debt is 0.97 times its own 6-year average.

Every figure in this lens

Except where said otherwise: Computed from the filing for 2025

  • Sales against its own 6-year average1.48
    Source
    computed
    Statement
    income
    Fiscal year
    2025
    Reported in
    SAR
  • Profit against its own 6-year average2.19
    Source
    computed
    Statement
    income
    Fiscal year
    2025
    Reported in
    SAR
  • Free cash flow against its own 6-year average1.37
    Source
    computed
    Statement
    income
    Fiscal year
    2025
    Reported in
    SAR
  • Debt against its own 6-year average0.97
    Source
    computed
    Statement
    income
    Fiscal year
    2025
    Reported in
    SAR
  • Price against its own 0-year averagen/aMarket data

    Not held.

    Source
    market
    Reported in
    SAR

Filed figures cite the filing they come from; figures marked Market data are quotes as of the date shown. Not a recommendation and not advice.

Past figures are not a forecast. Anything we modelled is labelled as ours. You can lose money on any security.